logo

BIIB

Biogen·NASDAQ
--
--(--)
--
--(--)
5.89 / 10
Netural

Biogen's fundamentals score an average 5.9/10. Strengths include solid asset and revenue management, but challenges arise in net-profit efficiency and current-asset turnover. Key metrics: Asset-MV (-0.50) in group 4, Revenue-MV (+0.31) in group 3, Profit-MV (+1.28) in group 1, and a high gross-profit margin of 74.9%. These factors collectively suggest a stable yet not outstanding business profile, supporting a neutral fundamental rating.

Fundamental(5.89)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value0.31
Score3/3
Weight40.32%
1M Return20.82%
Inventory turnover ratio
Value0.82
Score2/3
Weight-2.97%
1M Return-2.63%
Gross profit margin (%)
Value74.92
Score2/3
Weight1.94%
1M Return1.47%
Profit-MV
Value1.28
Score2/3
Weight11.72%
1M Return7.79%
PB-ROE
Value-0.34
Score1/3
Weight10.82%
1M Return7.02%
Current assets turnover ratio
Value0.93
Score1/3
Weight-0.59%
1M Return-0.48%
Fixed assets turnover ratio
Value2.19
Score2/3
Weight0.15%
1M Return0.12%
Asset-MV
Value-0.50
Score3/3
Weight27.21%
1M Return14.99%
Cash-MV
Value1.12
Score2/3
Weight11.74%
1M Return7.73%
Net profit / Total profit (%)
Value83.21
Score0/3
Weight-0.35%
1M Return-0.30%
Is BIIB undervalued or overvalued?
  • BIIB scores 5.89/10 on fundamentals and holds a Fair valuation at present. Backed by its 7.39% ROE, 13.07% net margin, 22.83 P/E ratio, 1.62 P/B ratio, and -21.23% earnings growth, these metrics solidify its Netural investment rating.